Gapping up
In reaction to strong earnings/guidance:
- SCS +13.9%
M&A news:
- MZOR +9.8% (to be acquired by Medtronic (MDT) for $58.50/share in cash)
Other news:
- OASM +27.7% (confirms the EMA's CHMP adopted a positive opinion recommending approval of Apealea in combination with carboplatin for treatment of adult patients with first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer)
- NBEV +16.2% (continued strength after closing up 80% on the day)
- AGEN +4.8% (enters into royalty purchase agreement with XOMA (XOMA))
- ACAD +4% (confirms FDA issues statement reaffirming the positive benefit-risk profile of NUPLAZID for patients with Parksinon's disease psychosis)
- ADT +3.1% (continued strength)
- VKTX +2.4% (prices public offering of 9,500,000 shares of its common stock at a price to the public of $18.50 per share)
- TXN +0.8% (raises quarterly dividend to $0.77/share from $0.62/share; authorizes repurchase of additional $12 bln of common stock)
- RDS.A +0.7% (Royal Dutch Shell may sell Gulf of Mexico assets to Focus Oil, according to Bloomberg sources)
Analyst comments:
- ADVM +7.8% (initiated with Overweight at Cantor Fitzgerald)
- HLIT +5.8% (initiated with Buy at Loop Capital)
- NTLA +4.1% (initiated with a Mkt Perform at Raymond James)
- LASR +2.4% (upgraded to Strong Buy from Outperform at Raymond James)
- CARA +1.9% (initiated with Overweight at Cantor Fitzgerald)
- UAA +1.9% (upgraded to Neutral from Underweight at JP Morgan)
- EDIT +1.8% (initiated with a Outperform at Raymond James)
- AYI +1.6% (upgraded to Outperform from Market Perform at Wells Fargo)
- IPGP +1.5% (upgraded to Strong Buy at Raymond James)
- T +1.3% (upgraded to Buy from Neutral at UBS)
- LGIH +1% (upgraded to Overweight from Neutral at JP Morgan)